Esperion Therapeutics has entered into a definitive agreement to acquire Corstasis Therapeutics, a privately held ...

Esperion has acquired Corstasis Therapeutics and its nasal spray Enbumyst, which was approved by the FDA six months ago.

Detailed price information for Esperion Theraptc (ESPR-Q) from The Globe and Mail including charting and trades.

Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to ...

Patients already had high NT-proBNP levels at baseline, though, raising questions about the quality of GDMT, Nancy Sweitzer ...

A secondary analysis of the SOUL trial shows significant improvement in heart failure outcomes with oral semaglutide vs placebo, consistent with the injectable formulation.

Many of us take medications to relieve pain, fight infections, or manage chronic conditions. While these therapies offer important health benefits, it's worth understanding a lesser-known ...

Esperion and Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative ...

Relief Cardiovascular has announced positive 90-day results from a study of its smart heart implant technology.

Editor’s note: This round‑up is based on press releases, peer‑reviewed publications, and company communications received in ...